CD274 and non-small cell lung carcinoma: No significant OS difference was observed for PD-L1 or brain metastases.<h4>Conclusions</h4>Real-world evidence confirms the long-term effectiveness and safety of pembrolizumab monotherapy for advanced NSCLC with PD-L1 ≥50%.